Synagis is the only FDA-approved medication to help protect high-risk babies lungs from severe RSV (Respiratory Syncytial Virus).

RSA symptoms are much like a moderate to severe cold. Premature babies and babies born with heart or lung conditions are at a higher risk of contacting RSV, which can lead to serious lung infections like bronchiolitis or pneumonia.

Death from RSV in infants is 10 times greater than that of the flu.

Synagis can protect premature babies and high-risk babies. Synagis is given as a monthly injection (every 28-30 days) during the RSV season, which runs from fall to spring.

For more information about our Synagis Program and the Clinical Policy and Criteria for Synagis, please read the following documents. We’ll be happy to answer any questions you have.